CANY
WST icon

Caxton Associates (New York)’s West Pharmaceutical WST Stock Holding History

Caxton Associates (New York)’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-3,036
Closed -$715K – 650
2022
Q4 		$715K Buy
3,036
+1,519
+100% +$360K 0.05% 179
2022
Q3 		$373K Buy
+1,517
New +$462K 0.05% 291
2017
Q3 		– Sell
-5,000
Closed -$473K – 638
2017
Q2 		$473K Sell
5,000
-600
-11% -$55.2K 0.02% 358
2017
Q1 		$457K Buy
+5,600
New +$468K ﹤0.01% 273

Other funds holding WST

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
APG Asset Management
APG Asset Management Amsterdam, Netherlands $40.7B AUM 39.97% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Caxton Associates (New York)'s WST Position: Q1 2023 in Review

Caxton Associates (New York) sold out of West Pharmaceutical (WST) in Q1 2023, closing a stake of 3,036 shares — an estimated $715K sold.

Caxton Associates (New York) first reported a position in WST in Q1 2017 and held it in 4 quarters. The position peaked at $715K in Q4 2022. 695 funds tracked by Wall St. Rank hold WST as of Q1 2023.

  • Caxton Associates (New York) reported no remaining West Pharmaceutical position as of Q1 2023 after selling out during the quarter.
  • Caxton Associates (New York) sold 3,036 West Pharmaceutical shares in Q1 2023, an estimated $715K.
  • Caxton Associates (New York) first reported a position in West Pharmaceutical in Q1 2017 and held it in 4 quarters.
  • Caxton Associates (New York)'s West Pharmaceutical position peaked at $715K in Q4 2022.
  • 695 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2023.

Based on Caxton Associates (New York)'s 13F filing for Q1 2023, filed 15 May 2023.